1-20 of 220 results for subject:Trastuzumab
Librarians' tools
- Search time
- 0.322 seconds
- Solr query time
- 0.003 seconds
- Search query
- subject:Trastuzumab
- We searched for
- subject_t:Trastuzumab OR subject_t:Herceptin OR subject_ses:10677
Type
House
Session
Year
Department
Member
More
Primary member
More
Answering member
Legislative stage
Legislation
Subject
More
Publisher
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits for (a) breast cancer patients and (b) NHS England of making permanent the reductions introduced during the covid-19 outbreak to (i) the number of doses of radiotherapy and (ii) cycles...
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits for (a) breast cancer patients and (b) NHS England of making permanent the reductions introduced during the covid-19 outbreak to (i) the number of doses of radiotherapy and (ii) cycles...
Breast cancer treatments are advancing all the time. Despite the pandemic, this year is no exception with developments having been made in both radiotherapy and chemotherapy treatments – both of which are likely to benefit breast cancer patients and the National Health Service as follows:
- The publication of the 10-year results of the FAST Trial, which looked at five fraction radiotherapy to treat early breast cancer, is an exciting breakthrough which enables people with breast cancer to be treated much more quickly and conveniently meaning fewer visits to hospital. All NHS radiotherapy providers in England are adopting this approach; and
- The PERSEPHONE trial evaluated the use of trastuzumab over a six month period versus a 12 month period to evaluate non-inferiority. In response to the pandemic, the National Institute for Health and Care Excellence developed interim guidance which recommended the use of the six month schedule. This approach means that patients attend hospital for a shorter overall period in order to reduce the risk of infection to vulnerable patients.
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential benefits to (a) patients and (b) NHS England of permanently reducing the number of doses of radiotherapy and cycles of adjuvant trastuzumab for breast cancer patients.
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential benefits to (a) patients and (b) NHS England of permanently reducing the number of doses of radiotherapy and cycles of adjuvant trastuzumab for breast cancer patients.
Breast cancer treatments are advancing all the time, and, despite the pandemic, this year is no exception with developments having been made in both radiotherapy and chemotherapy treatments – both of which are likely to benefit breast cancer patients and the National Health Service as follows:
- The publication of the ten-year results of the FAST Trial, which looked at five fraction radiotherapy to treat early breast cancer, is an exciting breakthrough which enables people with breast cancer to be treated much more quickly and conveniently meaning fewer visits to hospital. All NHS radiotherapy providers in England are adopting this approach; and
- The PERSEPHONE trial evaluated the use of trastuzumab over a six month period versus a 12 month period to evaluate non-inferiority. In response to the pandemic, the National Institute for Health and Care Excellence developed interim guidance which recommended the use of the six month schedule. This approach means that patients attend hospital for a shorter overall period in order to reduce the risk of infection to vulnerable patients.
How and if these treatments become part of the standard of care for breast cancer patients will be determined by the breast cancer clinical community, working in partnership with NHS England, and guided by research findings as they emerge.
To ask the Secretary of State for Health, whether NHS England has provided any guidance to hospital trusts and clinicians on the introduction of a biosimilar of Herceptin (trastuzumab) for breast cancer.
To ask the Secretary of State for Health, whether NHS England has provided any guidance to hospital trusts and clinicians on the introduction of a biosimilar of Herceptin (trastuzumab) for breast cancer.
A final date for the availability of a biosimilar of Herceptin (trastuzumab) has yet to be agreed. Therefore NHS England has not yet issued any guidance on the introduction of a biosimilar of Herceptin (trastuzumab) for breast cancer. However, NHS England has discussed the introduction and uptake of biosimilar trastuzumab with the Cancer Vanguard. The Vanguard is a group of National Health Service trusts looking at developing new models of care and providing replicable models for cancer care nationally that will act as blueprints for the NHS.
The Cancer Vanguard will provide guidance and supporting documentation to hospital trusts and clinicians in the same way that documents were provided to support the introduction of biosimilar rituximab. Once a firm date is known, NHS trusts will be contacted regarding the availability of biosimilar trastuzumab and what they must do to ensure uptake. This will include linkages to the supporting documents issued by the Vanguard.
To ask the Secretary of State for Health, what the timetable is for the introduction of herceptin on the NHS as a treatment for (a) rare forms of cancer and (b) lacrimal gland carcinoma.
To ask the Secretary of State for Health, what the timetable is for the introduction of herceptin on the NHS as a treatment for (a) rare forms of cancer and (b) lacrimal gland carcinoma.
Herceptin is currently licensed for use in the United Kingdom as a treatment for specific types of breast and gastric cancer, and has been recommended by the National Institute for Health and Care Excellence (NICE) in technology appraisal guidance for use in patients meeting specific clinical criteria. Herceptin is routinely available to eligible National Health Service patients in line with NICE’s recommendations.
Herceptin is not currently licensed for other rare forms of cancer, including lacrimal gland carcinoma, and has therefore not been subject to NICE appraisal for these indications.
To ask the Secretary of State for Health pursuant to the written ministerial statement of 12 June 2006, Official Report, column 47WS, on Herceptin, whether she has received a progress report from the National Cancer Director on the availability of HER2 testing to all newly diagnosed breast cancer patients of...
To ask the Secretary of State for Health pursuant to the written ministerial statement of 12 June 2006, Official Report, column 47WS, on Herceptin, whether she has received a progress report from the National Cancer Director on the availability of HER2 testing to all newly diagnosed breast cancer patients of...
To ask the Secretary of State for Health what estimate she has made of the cost of providing (a) herceptin for breast cancer and (b) alimta for mesothelioma for each patient with such diseases in the South West of England, broken down by primary care trust area.
To ask the Secretary of State for Health what estimate she has made of the cost of providing (a) herceptin for breast cancer and (b) alimta for mesothelioma for each patient with such diseases in the South West of England, broken down by primary care trust area.
To ask the Secretary of State for Health what assessment she has made of the geographical consistency of testing of women newly-diagnosed with breast cancer for suitability for treatment with herceptin.
To ask the Secretary of State for Health what assessment she has made of the geographical consistency of testing of women newly-diagnosed with breast cancer for suitability for treatment with herceptin.
On 12 June 2006, official report, columns 47-48WS I updated the House on Herceptin, following the announcement of its licence for early breast cancer and the publication of the National Institute for Health and Clinical Excellence’s (NICE) draft recommendations on its use. In that written statement, I promised to update...
On 12 June 2006, official report, columns 47-48WS I updated the House on Herceptin, following the announcement of its licence for early breast cancer and the publication of the National Institute for Health and Clinical Excellence’s (NICE) draft recommendations on its use. In that written statement, I promised to update...
My right honourable friend the Secretary of State for Health (Patricia Hewitt) has made the following Written Statement. On 12 June 2006 (Official Report, cols. 47-48WS) I updated the House on Herceptin, following the announcement of its licence for early breast cancer and the publication of the draft recommendations of...
My right honourable friend the Secretary of State for Health (Patricia Hewitt) has made the following Written Statement. On 12 June 2006 (Official Report, cols. 47-48WS) I updated the House on Herceptin, following the announcement of its licence for early breast cancer and the publication of the draft recommendations of...
To ask the Secretary of State for Health whether Herceptin will be available on the NHS in Gloucestershire in 2006.
To ask the Secretary of State for Health whether Herceptin will be available on the NHS in Gloucestershire in 2006.
To ask the Secretary of State for Health pursuant to the answer of 21 June, Official Report, column 1936W, on breast cancer, in what circumstances a breast cancer patient may not benefit from Herceptin.
To ask the Secretary of State for Health pursuant to the answer of 21 June, Official Report, column 1936W, on breast cancer, in what circumstances a breast cancer patient may not benefit from Herceptin.
On 24 May Roche, the manufacturers of Herceptin (Trastuzumab), announced that the European Commission had granted a licence extension for Herceptin to include use in patients with HER2-positive early breast cancer. On 9 June the National Institute for Health and Clinical Excellence (NICE) published its draft guidance on Herceptin. This...
On 24 May Roche, the manufacturers of Herceptin (Trastuzumab), announced that the European Commission had granted a licence extension for Herceptin to include use in patients with HER2-positive early breast cancer. On 9 June the National Institute for Health and Clinical Excellence (NICE) published its draft guidance on Herceptin. This...
To ask the Secretary of State for Health if she will meet Shropshire Primary Care Trust to discuss the provision of Herceptin to those with early stage breast cancer in Shropshire.
To ask the Secretary of State for Health if she will meet Shropshire Primary Care Trust to discuss the provision of Herceptin to those with early stage breast cancer in Shropshire.
My right honourable friend the Secretary of State for Health has made the following Written Ministerial Statement. On 24 May Roche, the manufacturers of Herceptin (trastuzumab), announced that the European Commission had granted a licence extension for Herceptin to include use in patients with HER2-positive early breast cancer. On 9...
My right honourable friend the Secretary of State for Health has made the following Written Ministerial Statement. On 24 May Roche, the manufacturers of Herceptin (trastuzumab), announced that the European Commission had granted a licence extension for Herceptin to include use in patients with HER2-positive early breast cancer. On 9...
May I also associate myself with the previous comments about Eric Forth? He was a most independent-minded Member and a splendid example to us all. I appreciate the fact that the new Leader of the House bothers to attend debates and statements. He came to the Opposition day health debate...
May I also associate myself with the previous comments about Eric Forth? He was a most independent-minded Member and a splendid example to us all. I appreciate the fact that the new Leader of the House bothers to attend debates and statements. He came to the Opposition day health debate...
As the hon. Gentleman mentions, I was indeed present for the Opposition day debate on the health service. I listened carefully to the opening speeches made by the Opposition spokesman and by my right hon. Friend the Secretary of State for Health. The hon. Gentleman’s criticisms of the way in...
As the hon. Gentleman mentions, I was indeed present for the Opposition day debate on the health service. I listened carefully to the opening speeches made by the Opposition spokesman and by my right hon. Friend the Secretary of State for Health. The hon. Gentleman’s criticisms of the way in...
To ask the Secretary of State for Health if she will make a statement on Government policy on the prescription of Herceptin for early stage breast cancer.
To ask the Secretary of State for Health if she will make a statement on Government policy on the prescription of Herceptin for early stage breast cancer.